PANAVANCE THERAPEUTICS
Panavance Therapeutics is a clinical-stage pharmaceutical company that advances the development of GP-2250 novel oncology therapeutics focused on improving the effectiveness of cancer treatments.
PANAVANCE THERAPEUTICS
Industry:
Pharmaceutical Therapeutics
Founded:
2021-01-01
Address:
Berwyn, Pennsylvania, United States
Country:
United States
Website Url:
http://www.panavance.com
Total Employee:
11+
Status:
Active
Contact:
+1.610.922.1910
Similar Organizations
Galimedix Therapeutics
Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments.
Ocunexus Therapeutics
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology.
Yamo Pharmaceuticals
Yamo Pharmaceuticals is a clinical-stage pharmaceutical company that develops L1-79, a novel therapy for Autism spectrum disorder.
Current Employees Featured
Official Site Inspections
http://www.panavance.com Semrush global rank: 5.18 M Semrush visits lastest month: 1.56 K
- Host name: 31.25.154.104.bc.googleusercontent.com
- IP address: 104.154.25.31
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Panavance Therapeutics"
Panavance - Novel Cancer Therapeutic - Giving Patients New Hope
It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, ... Panavance Therapeutics Announces …See details»
Leadership - Panavance Therapeutics
Greg Bosch brings over 35 years in healthcare to Panavance with global leadership of commercial, operations, and R&D teams. His general management experience in the life …See details»
About Panavance Therapeutics
Panavance Therapeutics is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (also known as GP-2250). Panavance, a US Delaware company located in Berwyn, PA, was …See details»
Panavance Therapeutics - Crunchbase Company Profile & Funding
Organization. Panavance Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Panavance Therapeutics is a clinical-stage …See details»
Panavance Therapeutics Inc. Management Team | Org Chart
The Panavance Therapeutics Inc. management team includes Greg Bosch (Chairman and CEO), Erich Platzer (Board Member), and Cindy Collins (Lead Director). Get Contact Info for All …See details»
Panavance Therapeutics Inc. | LinkedIn
Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed.See details»
Panavance Details IND Prep Ahead Of FDA Submission For …
Oct 23, 2024 Panavance CEO Greg Bosch discusses the company’s pursuit of a second trial for misetionamide, walking us through IND preparations, CRO selection, and securing funding. ...See details»
Panavance Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Explore Panavance Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 news, Disease Domain:Endocrinology and Metabolic Disease ...See details»
Panavance Therapeutics - Contacts, Employees, Board Members, …
Panavance Therapeutics is a clinical-stage pharmaceutical company that develops novel therapeutics for effective cancer treatments. ... Pricing. Log In. Log In. Experience the new …See details»
Panavance Therapeutics to Present at the Biotechnology
May 24, 2023 Panavance, a US Delaware company, is located in Berwyn, PA. It was founded in 2021 and is a subsidiary of Swiss privately held Ed. Geistlich Söhne AG für Chemische Industrie.See details»
Panavance Therapeutics Inc. - VentureRadar
Panavance’s lead program, GP-2250, is a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer …See details»
Panavance Therapeutics
It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, but has truly unique science that ... We are …See details»
Panavance Therapeutics Company Profile | Management and
Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, GP-2250 (also known as misetionamide). Panavance was …See details»
Panavance Therapeutics Inc. Created to Transform Cancer Treatment
Jan 11, 2022 Panavance is not responsible for the contents of third-party websites. About Panavance Therapeutics Inc. Panavance Therapeutics Inc. is a US, clinical-stage …See details»
Panavance Therapeutics | Life Sciences PA - Default Site
In June 2021, Panavance Therapeutics Inc, a clinical stage biotechnology company focused on novel oncology therapeutics, was incorporated in Delaware. The Company’s lead product …See details»
Panavance Therapeutics - PitchBook
Panavance Therapeutics General Information Description. Operator of a clinical-stage pharmaceutical company intended to improve the effectiveness of cancer treatments and the …See details»
Resource Center - Panavance Therapeutics
Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention. Read Release . Press Release – April 17, 2023 ... Greg Bosch, …See details»
Panavance Therapeutics - Overview, News & Similar companies
Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, GP-2250 (also known as mi setionamide). Panavance was …See details»
Panavance Therapeutics Inc. Created to Transform Cancer Treatment
Jan 24, 2022 The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action. Excerpt from the Press Release: Panavance Therapeutics …See details»
Interim data reveals potential of new pancreatic cancer drug
Oct 23, 2024 Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The Phase I dose escalation …See details»